170 related articles for article (PubMed ID: 11137241)
21. Protection against herpes B virus infection in rabbits with a recombinant vaccinia virus expressing glycoprotein D.
Bennett AM; Slomka MJ; Brown DW; Lloyd G; Mackett M
J Med Virol; 1999 Jan; 57(1):47-56. PubMed ID: 9890421
[TBL] [Abstract][Full Text] [Related]
22. Epitope mapping of human monoclonal antibodies recognizing conformational epitopes within HTLV type 1 gp46, employing HTLV type 1/2 envelope chimeras.
Hadlock KG; Yang Q; Rowe J; Foung SK
AIDS Res Hum Retroviruses; 2002 Jan; 18(1):57-70. PubMed ID: 11804557
[TBL] [Abstract][Full Text] [Related]
23. Influence of epitope polarity and adjuvants on the immunogenicity and efficacy of a synthetic peptide vaccine against Semliki Forest virus.
Fernández IM; Snijders A; Benaissa-Trouw BJ; Harmsen M; Snippe H; Kraaijeveld CA
J Virol; 1993 Oct; 67(10):5843-8. PubMed ID: 7690411
[TBL] [Abstract][Full Text] [Related]
24. Targeted expression of HTLV-I envelope proteins in muscle by DNA immunization of mice.
Armand MA; Grange MP; Paulin D; Desgranges C
Vaccine; 2000 Apr; 18(21):2212-22. PubMed ID: 10717340
[TBL] [Abstract][Full Text] [Related]
25. Protective efficacy of multiepitope human leukocyte antigen-A*0201 restricted cytotoxic T-lymphocyte peptide construct against challenge with human T-cell lymphotropic virus type 1 Tax recombinant vaccinia virus.
Sundaram R; Lynch MP; Rawale S; Dakappagari N; Young D; Walker CM; Lemonnier F; Jacobson S; Kaumaya PT
J Acquir Immune Defic Syndr; 2004 Nov; 37(3):1329-39. PubMed ID: 15483462
[TBL] [Abstract][Full Text] [Related]
26. The effects of a flanking sequence on the immune response to a B and a T cell epitope from the fusion protein of measles virus.
Partidos CD; Steward MW
J Gen Virol; 1992 Aug; 73 ( Pt 8)():1987-94. PubMed ID: 1379626
[TBL] [Abstract][Full Text] [Related]
27. Immunological analysis of the protective responses to the chimeric synthetic peptide representing T- and B-cell epitopes from the fusion protein of measles virus.
Obeid OE; Stanley CM; Steward MW
Virus Res; 1996 Jun; 42(1-2):173-80. PubMed ID: 8806185
[TBL] [Abstract][Full Text] [Related]
28. Peptide vaccines incorporating a 'promiscuous' T-cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity.
Kaumaya PT; Kobs-Conrad S; Seo YH; Lee H; VanBuskirk AM; Feng N; Sheridan JF; Stevens V
J Mol Recognit; 1993 Jun; 6(2):81-94. PubMed ID: 7508238
[TBL] [Abstract][Full Text] [Related]
29. Chimeric peptide vaccine composed of B- and T-cell epitopes of human T-cell leukemia virus type 1 induces humoral and cellular immune responses and reduces the proviral load in immunized squirrel monkeys (Saimiri sciureus).
Kazanji M; Heraud JM; Merien F; Pique C; de Thé G; Gessain A; Jacobson S
J Gen Virol; 2006 May; 87(Pt 5):1331-1337. PubMed ID: 16603536
[TBL] [Abstract][Full Text] [Related]
30. Priming of measles virus-specific CTL responses after immunization with a CTL epitope linked to a fusogenic peptide.
Partidos CD; Vohra P; Steward MW
Virology; 1996 Jan; 215(1):107-10. PubMed ID: 8553582
[TBL] [Abstract][Full Text] [Related]
31. A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses.
Dakappagari NK; Pyles J; Parihar R; Carson WE; Young DC; Kaumaya PT
J Immunol; 2003 Apr; 170(8):4242-53. PubMed ID: 12682258
[TBL] [Abstract][Full Text] [Related]
32. Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine.
Dakappagari NK; Douglas DB; Triozzi PL; Stevens VC; Kaumaya PT
Cancer Res; 2000 Jul; 60(14):3782-9. PubMed ID: 10919651
[TBL] [Abstract][Full Text] [Related]
33. Mucosal immunization with a measles virus CTL epitope encapsulated in biodegradable PLG microparticles.
Partidos CD; Vohra P; Jones DH; Farrar GH; Steward MW
J Immunol Methods; 1996 Sep; 195(1-2):135-8. PubMed ID: 8814328
[TBL] [Abstract][Full Text] [Related]
34. Cross-reactive and group-specific immune responses to a neutralizing epitope of the human respiratory syncytial virus fusion protein.
Corvaisier C; Bourgeois C; Pothier P
Arch Virol; 1997; 142(6):1073-86. PubMed ID: 9228999
[TBL] [Abstract][Full Text] [Related]
35. Identification of a novel neutralization epitope on envelope gp46 antigen of human T-cell-leukemia virus-type-II (HTLV-II).
Tanaka Y; Tanaka R; Hoshino H
Int J Cancer; 1994 Dec; 59(5):655-60. PubMed ID: 7525496
[TBL] [Abstract][Full Text] [Related]
36. Identification of exposed epitopes on the envelope glycoproteins of human T-cell lymphotropic virus type I (HTLV-I).
Grange MP; Rosenberg AR; Horal P; Desgranges C
Int J Cancer; 1998 Mar; 75(5):804-13. PubMed ID: 9495252
[TBL] [Abstract][Full Text] [Related]
37. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia--RSV recombinants or RSV.
Connors M; Collins PL; Firestone CY; Sotnikov AV; Waitze A; Davis AR; Hung PP; Chanock RM; Murphy BR
Vaccine; 1992; 10(7):475-84. PubMed ID: 1609551
[TBL] [Abstract][Full Text] [Related]
38. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
Kang CY; Luo L; Wainberg MA; Li Y
Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
[TBL] [Abstract][Full Text] [Related]
39. Increased immunogenicity and protective efficacy in outbred and inbred mice by strategic carboxyl-terminal truncation of Japanese encephalitis virus envelope glycoprotein.
Jan LR; Yang CS; Henchal LS; Sumiyoshi H; Summers PL; Dubois DR; Lai CJ
Am J Trop Med Hyg; 1993 Mar; 48(3):412-23. PubMed ID: 8385887
[TBL] [Abstract][Full Text] [Related]
40. Adjuvant-independent enhanced immune responses to recombinant herpes simplex virus type 1 glycoprotein D by fusion with biologically active interleukin-2.
Hazama M; Mayumi-Aono A; Asakawa N; Kuroda S; Hinuma S; Fujisawa Y
Vaccine; 1993; 11(6):629-36. PubMed ID: 8391739
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
